In breast cancer patients, there is emerging evidence for prescribing beta-blockers or angiotensin converting enzyme (ACE) inhibitors upfront in patients receiving chemotherapy and/or trastuzumab for prevention of CTRCD [24–26]. This evidence concerns the gene ACE and breast carcinoma.